Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Surveys reveal difficulties associated with daily pills and a desire for long-acting injectable therapy.
Over $12 million in grants has been awarded to the Wistar Institute to research the links between opioid receptors and immune activation.
Merck’s experimental HIV drug proves effective and well tolerated
A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
A high proportion of people with HIV suffer from anxiety, which is associated with lower rates of HIV treatment and adherence to treatment.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
These medications can now be used by people on stable antiretroviral treatment with undetectable viral load.
Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.
Some groups, however, including Black and Latino men and homeless people, are not faring as well as others.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
Cabotegravir plus rilpivirine maintenance therapy worked equally well when taken monthly or every two months.
French study finds taking meds for four days with three days off is as effective as daily therapy—and costs 43% less.
Doctors attribute the drop to increased testing and U=U.
The Food and Drug Administration has approved a new treatment for people living with HIV.
A recent review of 54 studies indicates that people living with HIV are at high risk for experiencing cardiac dysfunction.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.